Hispidulin Attenuates Cardiac Hypertrophy by Improving Mitochondrial Dysfunction.

Area of Science:

• Cardiovascular Biology
• Mitochondrial Medicine
• Pharmacology

Background:

• Cardiac hypertrophy is a precursor to heart failure, driven by cellular stress.
• Mitochondrial dysfunction is a critical factor in the progression from cardiac hypertrophy to heart failure.
• Hispidulin, a flavonoid, shows potential in improving energy metabolism and reducing oxidative stress.

Purpose of the Study:

• To investigate the effects of hispidulin on cardiac hypertrophy.
• To elucidate the underlying molecular mechanisms of hispidulin's action, particularly its impact on mitochondrial function.
• To determine if Sirt1 is a key mediator of hispidulin's protective effects.

Main Methods:

• In vivo studies using pressure overload models to induce cardiac hypertrophy.
• In vitro studies using phenylephrine to induce cardiomyocyte hypertrophy.
• Assessment of mitochondrial function, including electron transport chain (ETC) expression, ATP production, and oxygen consumption rates (OCR).
• Investigation of Sirt1's role using a specific inhibitor (EX527).

Main Results:

• Hispidulin significantly inhibited pressure overload-induced cardiac hypertrophy and improved cardiac function.
• Hispidulin treatment enhanced mitochondrial function, increased ATP production, elevated OCR, and reduced oxidative stress.
• Hispidulin upregulated Sirt1 expression, and inhibiting Sirt1 abolished hispidulin's protective effects.

Conclusions:

• Hispidulin demonstrates significant antihypertrophic effects and improves cardiac function.
• Hispidulin ameliorates cardiac hypertrophy by enhancing mitochondrial function and reducing oxidative stress.
• Sirt1 is a critical downstream target of hispidulin in mediating its cardioprotective effects against cardiac hypertrophy.